Rite Aid and Albertsons Mutually Move to Cancel Merger

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rite Aid and Albertsons Mutually Move to Cancel Merger

© Ildar Sagdejev (Specious) / Wikimedia Commons

Rite Aid Corp. (NYSE: RAD) shares were crushed early on Thursday after the company announced a mutual agreement with Albertsons to terminate the merger ahead of the vote.

One of the main takeaways from this is that neither Rite Aid nor Albertsons will be responsible for any payments to the other party as a result of the termination of the merger agreement.

Albertsons was originally offering either a share of its stock and $1.83 in cash or slightly more than one Albertsons share for every 10 Rite Aid shares. The merger would have created a new company with roughly $83 billion in annual sales and 4,900 locations across the United States.

Rite Aid also announced that its board of directors is evaluating governance changes at the company. Although, the company did not go too much into detail about how it plans to accomplish this.

[nativounit]

John Standley, Rite Aid’s board chair and chief executive, commented:

While we believed in the merits of the combination with Albertsons, we have heard the views expressed by our stockholders and are committed to moving forward and executing our strategic plan as a standalone company. We remain focused on leveraging our network of conveniently located retail pharmacies, our EnvisionRxOptions PBM and our trusted brand of health and wellness offerings. We will continue building momentum for key areas of our business like our innovative Wellness store format, highly successful customer loyalty program and expanded pharmacy service offerings, as we also enhance our omni-channel and own brand offerings to strengthen our competitive position and create long-term value for stockholders.

Shares of Rite Aid were last seen down more than 11% at $1.54 Thursday morning, with a consensus analyst price target of $1.97 and a 52-week trading range of $1.38 to $2.80.

[recirclink id=484735]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618